Empowering mental health professionals with peer-reviewed psychiatric research and insights
Page 3
More JCP Articles
Original Research
Lack of Generalizability of PTSD Treatment Trials: The Recent Brexpiprazole-Sertraline Trials as an Example
November 26, 2025
In an outpatient psychiatry sample, nearly 95% of patients who want treatment for PTSD would not have qualified for the trials of brexpiprazole-sertraline for PTSD.
Original Research
Triple Network Model–Based Functional Dysconnectivity in Young People With Major Affective Disorders With or Without Suicidal Ideation
November 19, 2025
In young people with major affective disorders, suicidality is associated with extensive functional dysconnectivity in the triple networks (default mode network, salience network, and frontoparietal network).
Original Research
Effect of Adjuvant Metformin on Adherence to and Persistence of Treatment With SGAs in Nondiabetic Patients
November 17, 2025
Use of metformin with second-generation antipsychotics (SGAs) was associated with improved adherence and persistence to SGAs at both 180- and 365-day follow-up in adults with Medicaid and commercial insurance.
Clinical and Practical Psychopharmacology
Acetaminophen Use in Pregnancy and Neurodevelopmental Disorders in Offspring: A Reasoned Evaluation of Risk
November 10, 2025
This article considers the background, questions, and evidence related to acetaminophen use in pregnancy and neurodevelopmental disorders in offspring, with reference to two recent large studies.
Original Research
Targeting Intolerance of Uncertainty during Pregnancy: A Randomized Controlled Trial to Prevent Postpartum Anxiety Disorders
November 5, 2025
A 6-week CBT protocol targeting intolerance of uncertainty significantly reduced the risk of postpartum anxiety disorder onset versus care as usual, and patient satisfaction with treatment was high.
Case Series
Esketamine Augmented With Dextromethorphan/Bupropion for Treatment Resistant Depression: A Case Series
November 3, 2025
Three patients with TRD who had no or partial response to esketamine monotherapy as part of a clinical trial received augmentation with dextromethorphan/bupropion 45 mg/105 mg daily.
